ELAB
Price
$2.15
Change
+$0.18 (+9.14%)
Updated
Dec 18, 04:59 PM (EDT)
REGN
Price
$714.62
Change
-$25.39 (-3.43%)
Updated
Dec 18, 04:59 PM (EDT)
44 days until earnings call
Ad is loading...

ELAB vs REGN

Header iconELAB vs REGN Comparison
Open Charts ELAB vs REGNBanner chart's image
Elevai Labs
Price$2.15
Change+$0.18 (+9.14%)
Volume$2.01K
CapitalizationN/A
Regeneron Pharmaceuticals
Price$714.62
Change-$25.39 (-3.43%)
Volume$13.61K
CapitalizationN/A
ELAB vs REGN Comparison Chart
Loading...
ELAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ELAB vs. REGN commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELAB is a Hold and REGN is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (ELAB: $1.97 vs. REGN: $740.01)
Brand notoriety: ELAB: Not notable vs. REGN: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ELAB: 40% vs. REGN: 116%
Market capitalization -- ELAB: $6.05M vs. REGN: $81.32B
ELAB [@Biotechnology] is valued at $6.05M. REGN’s [@Biotechnology] market capitalization is $81.32B. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELAB’s FA Score shows that 1 FA rating(s) are green whileREGN’s FA Score has 0 green FA rating(s).

  • ELAB’s FA Score: 1 green, 4 red.
  • REGN’s FA Score: 0 green, 5 red.
According to our system of comparison, REGN is a better buy in the long-term than ELAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELAB’s TA Score shows that 5 TA indicator(s) are bullish while REGN’s TA Score has 4 bullish TA indicator(s).

  • ELAB’s TA Score: 5 bullish, 3 bearish.
  • REGN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ELAB is a better buy in the short-term than REGN.

Price Growth

ELAB (@Biotechnology) experienced а -23.35% price change this week, while REGN (@Biotechnology) price change was -4.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.92%, and the average quarterly price growth was +0.65%.

Reported Earning Dates

REGN is expected to report earnings on Jan 31, 2025.

Industries' Descriptions

@Biotechnology (-6.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REGN($81.3B) has a higher market cap than ELAB($6.05M). REGN YTD gains are higher at: -15.744 vs. ELAB (-99.461). REGN has higher annual earnings (EBITDA): 5.5B vs. ELAB (-4.75M). REGN has more cash in the bank: 9.8B vs. ELAB (100K). ELAB has less debt than REGN: ELAB (140K) vs REGN (2.7B). REGN has higher revenues than ELAB: REGN (13.8B) vs ELAB (2.45M).
ELABREGNELAB / REGN
Capitalization6.05M81.3B0%
EBITDA-4.75M5.5B-0%
Gain YTD-99.461-15.744632%
P/E RatioN/A18.30-
Revenue2.45M13.8B0%
Total Cash100K9.8B0%
Total Debt140K2.7B0%
FUNDAMENTALS RATINGS
REGN: Fundamental Ratings
REGN
OUTLOOK RATING
1..100
9
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
PROFIT vs RISK RATING
1..100
41
SMR RATING
1..100
51
PRICE GROWTH RATING
1..100
65
P/E GROWTH RATING
1..100
90
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ELABREGN
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
72%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
71%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
54%
MACD
ODDS (%)
Bullish Trend 3 days ago
57%
Bullish Trend 2 days ago
59%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
55%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
60%
Advances
ODDS (%)
Bullish Trend 9 days ago
84%
Bullish Trend 10 days ago
63%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 3 days ago
51%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
52%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
57%
View a ticker or compare two or three
Ad is loading...
ELAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TRMVX27.81N/A
N/A
SEI Large Cap Value F (SIMT)
PWJDX31.17N/A
N/A
PGIM Jennison International Opps R4
MSBKX8.41-0.03
-0.36%
Morgan Stanley Global Focus Rl Est C
HFECX43.63-0.26
-0.59%
Janus Henderson European Focus C
HEOFX16.91-0.13
-0.76%
Hartford Climate Opportunities F

ELAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELAB has been loosely correlated with EPIX. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if ELAB jumps, then EPIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELAB
1D Price
Change %
ELAB100%
-4.37%
EPIX - ELAB
33%
Loosely correlated
+0.61%
REGN - ELAB
23%
Poorly correlated
+2.09%
MTNB - ELAB
21%
Poorly correlated
+10.16%
LXRX - ELAB
20%
Poorly correlated
-4.64%
ENGN - ELAB
17%
Poorly correlated
-0.16%
More

REGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, REGN has been loosely correlated with MTNB. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then MTNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REGN
1D Price
Change %
REGN100%
+2.09%
MTNB - REGN
42%
Loosely correlated
+10.16%
IDYA - REGN
39%
Loosely correlated
+1.07%
VRTX - REGN
36%
Loosely correlated
+0.25%
INVA - REGN
35%
Loosely correlated
-0.27%
TECH - REGN
34%
Loosely correlated
-1.17%
More